期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌中的VEGF表达及临床意义 被引量：8

下载PDF
导出
摘要 目的探讨三阴性乳腺癌中的血管内皮生长因子(VEGF)表达及临床意义。方法应用免疫组织化学方法检测三阴性乳腺癌患者69例和非三阴性乳腺癌患者293例肿瘤组织VEGF表达情况,分析VEGF表达与临床病理特点的关系。结果三阴性乳腺癌组VEGF阳性率为46.38%(32/69),明显高于非三阴性乳腺癌组33.45%(98/293)(P<0.05)。三阴性乳腺癌组VEGF表达与患者的年龄、肿瘤直径、病理类型、临床分期无关(P>0.05),而与淋巴结转移状态有关(P<0.05)。结论三阴性乳腺癌组织VEGF高表达,VEGF表达与淋巴结转移有关。
作者 蒋洪棉 朱世龙 李辛辛 黎木燕
机构地区 广西医科大学附属南宁市第一人民医院病理科
出处 《广西医学》 CAS 2013年第6期743-744,共2页 Guangxi Medical Journal
关键词 乳腺癌 血管内皮生长因子 免疫组织化学
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000 [ J ]. Int J cancer, 2001,94 (2) :153 - 155.
  • 2Bauer KR, Brown M, Cress B.D, et al. Descriptive analysis d estrogen receptor ( ER )-negative, progesterone receptor (PB)-negative,and HEB2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry[J]. Cancer,2007, 109(9) :1 721 -1 728.
  • 3Haffty BG,Yang Q,Reiss M,et al. Locovegional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer [ J ]. J Clin Oncol, 2006,24 (36) : 5 652 -5 657.
  • 4Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer:cllnical features and patterns of recurrence [J]. Clin Cancer Res,2007,13(15 Ptl) :4 429 -4 434.
  • 5Cleator S, HeUer W, Coombes RC. Triple-negative breast cancer: therapeutic options[ J ]. Lancet Oncol,2007,8 (3) : 235 - 244.
  • 6Rakha EA,EI-Sayed ME,Green AR,et al. Prognostic mark- ers in triple-negative breast cancer [ J ]. Cancer, 2,007,109 (1) :25 -32.
  • 7Linderholm BK,Lindahl T,Holmberg L,et al. The expres- sion of vascular endothelial growth factor correlates with mutunt p53 and poor prognosis in human breast cancer [J]. Cancer Res,2001,61(5) :2 256 -2 260.
  • 8刘畅,曹仁贤,陶松桔.VEGF在乳腺癌组织与血清中的表达及临床意义[J].实用预防医学,2012,19(8):1245-1247. 被引量：4
  • 9张明彩.乳腺癌组织中VEGF的表达及临床意义[J].医学信息（医药版）,2008(10):63-65. 被引量：1
  • 10Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expres- sion in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression [ J ]. Turnout Biol, 2011,32 (1) :23 -32.

二级参考文献13

  • 1唐明朝,李代强.乳腺癌CD105和CD34标记的微血管密度差异及与VEGF的关系[J].实用预防医学,2005,12(4):801-804. 被引量：6
  • 2李恩孝,吴胤瑛,施璠.靶向VEGF治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,14(3):370-372. 被引量：6
  • 3Oliveira VM, Aldrighi JM, Bagnoli F. Evidence of the action of bisphosphonates in the prevention of breast eancer[J]. Rev Assoc Med Bras, 2011, 57(1): 7-8.
  • 4Suzuki K, Hagashy N, Miyamoto Y, et al. Expression of vascular per- meability factor vascular endothelial growth factor in human hepatocellular carcinoma J[J]. Cancer Res, 1996, 56(13) : 3004- 3009.
  • 5Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma; correlation with VEGF - A and MTA1 expression [J ]. Tumour Biol, 2011, 32 ( 1 ) : 23 - 32.
  • 6Heer N, Kumar H, Read JR, et al. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen recep- tor status[J]. Clin Cancer Res, 2001, 7:3491-3494.
  • 7Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF- A and MTA1 expression [ J ]. Tumour Biol, 2011, 32 ( 1 ) : 23 - 32.
  • 8Derleth C, Mayer IA. Antiangiogenic therapies in early- stage breast cancer[J]. Clin Breast Cancer, 2010, 10(Suppl 1) : E23 - 31.
  • 9Das S, Ladell DS, Podgrabinska S, et al. Vascular endothelial growth factor- C induces lymphangitie careinomatosis, an extremely aggressive form of lung metastases[J], Cancer Res, 2010, 70(5): 1814- 1824.
  • 10Ran S, Volk L, Hall K, et al. Lymphartgiogenesis and lymphatic metastasis in breast cancer[J]. Pathophysiology, 2010,17(4) : 229 - 251.

共引文献3

同被引文献53

  • 1陆应麟.上皮生长因子受体在肿瘤转移中的作用研究进展[J].解放军医学情报,1994,8(6):311-312. 被引量：1
  • 2Sledge GW Jr. VEGF-targeting therapy for breast cancer[J].{H}Journal of Mammary Gland Biology and Neoplasia,2005,(04):319-323.
  • 3KEAM B,IM S A,LEE K H,et al.Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis[J].Breast Cancer Res,2011,13(2):22.
  • 4Fan L,Strasser-Weippl K,Li JJ,et a1.Breast cancer in China[J].Lancet Oncol,2014,15(7):279-89.
  • 5Jemal A,Bray F,Center MM,et a1.Global cancer statics.CA Cancer J Clin,2011,61(2):134.
  • 6Peng R,Wang S,Shi Y,et a1.Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival:a retrospective matched case-control study[J].Breast,2011,20(6):568-573.
  • 7Hanrahan EO,Ryan AJ,Mann H,et a1.Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.Clin Cancer Res.2009,15(10):3600-9.
  • 8El-Zaemey S,Nagi N,Fritschi L,et a1.Breast cancer among Yemeni women using the National Oncology Centre Registry 2004-2010[J].Cancer Epidemiol,2012,36(3):249-253.
  • 9Kwon JH,Kim YJ,Lee KW,et a1.Triple negativity and young age as prognostic factors in lymph nodenegative invasive ductal carcinoma of 1cm or less[J].BMC Cancer,2010,10:557.
  • 10Sharma G,Mirza S,Parshad R,et al.Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma:correlation with VEGF-A and MTAL expression[J].Tumour Biol,2011,25(32):23-32.

引证文献8

二级引证文献28

广西医学
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部